Medicef Pharma - Due diligence report

A 360° intelligence report on Medicef Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…

2012-10-16 Kasauli, Himachal Pradesh Active Unlisted Active Compliant
Share
Connect MCP
MP Medicef Pharma
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Medicef Pharma — 360° Intelligence Report

Generated from MCA filings & public records
60/100
Trust Score
Moderate

Medicef Pharma is assessed as Moderate with a Trust Score of 60/100. Medicef Pharma is an active public limited indian non-government company incorporated in 2012, operating in the Pharma sector. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 27 Sep 2026 from the latest processed filings. Medicef Pharma Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
60/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
10/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
35/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Externally credit-rated (BBB-).

Charges position: 4 open (36.92 cr) · 2 satisfied (10.45 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Dbs Bank Ltd1 48.0 cr
Others5 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 75/100
NameDIN / PANDesignationAppointedTenureDIN status
NILESH NARENDRAKUMAR RANKA 01234567 Director 01/04/2018 6 yrs Approved
Parveen Kumar 01234567 Director 01/04/2018 6 yrs Approved
Dhananjay Kumar Vishwakarma 01234567 Director 01/04/2018 6 yrs Approved
Anish Kumar Rana 01234567 Director 01/04/2018 6 yrs Approved
Satyanaraian Gupta 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • 7 director exits in 3 years - high churn.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 55 · Distress 35
Growth signals & trust indicators
Asset base grew 38% - capacity expansion.
Operating for 13+ years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 1.42 in a year.
Negative net worth.
5 director exits within 2 years.
4 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence64/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment45/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 36.92 cr already registered.
  • Compliance record supports lending.
Investor view40/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
29 Sep 2024
Director ceased
NILESH NARENDRAKUMAR RANKA
Director ceased
Parveen Kumar
Director ceased
Dhananjay Kumar Vishwakarma
Director ceased
Anish Kumar Rana
Director ceased
Satyanaraian Gupta
31 Mar 2024
Latest balance sheet
Filed with ROC
19 Feb 2024
Charge created
Dbs Bank Ltd - 25.00 cr
15 Feb 2024
Charge satisfied
Others
12 Feb 2024
Director appointed
NILESH NARENDRAKUMAR RANKA (Director)
30 Jan 2024
Director ceased
VIJAY KUMAR AGGARWAL
29 Jan 2024
Director appointed
Parveen Kumar (Director)
Director appointed
Dhananjay Kumar Vishwakarma (Director)
Director appointed
Anish Kumar Rana (Director)
Director appointed
Satyanaraian Gupta (Director)
10

Key Observations

Auto-generated from the data above
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB- from Crisil.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
11

Peers & Related Companies

Full peer comparison →
Peer companies will appear here as our matching engine processes this industry.
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Medicef Pharma before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Medicef Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 55/100, margin trends, ownership structure and peer set for Medicef Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 60/100, distress signals and MSME payment-delay disclosures - know whether Medicef Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Medicef Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Medicef Pharma an active company?

Medicef Pharma has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Medicef Pharma financially healthy?

Medicef Pharma has a Financial Health Score of 10/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Medicef Pharma?

Its overall Trust Score is 60/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Medicef Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.

Does Medicef Pharma have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Medicef Pharma up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Medicef Pharma?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.